Review

COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates

Malik Sallam

Abstract: Utility of vaccine campaigns to control coronavirus 2019 disease (COVID-19) is not merely dependent on vaccine efficacy and safety. Vaccine acceptance among the general public and healthcare workers appears to have a decisive role in the successful control of the pandemic. The aim of this review was to provide an up-to-date assessment of COVID-19 vaccination acceptance rates worldwide. A systematic search of the peer-reviewed English survey literature indexed in PubMed was done on 25 December 2020. Results from 31 peer-reviewed published studies met the inclusion criteria and formed the basis for the final COVID-19 vaccine acceptance estimates. Survey studies on COVID-19 vaccine acceptance rates were found from 33 different countries. Among adults representing the general public, the highest COVID-19 vaccine acceptance rates were found in Ecuador (97.0%), Malaysia (94.3%), Indonesia (93.3%) and China (91.3%). However, the lowest COVID-19 vaccine acceptance rates were found in Kuwait (23.6%), Jordan (28.4%), Italy (53.7%), Russia (54.9%), Poland (56.3%), US (56.9%), and France (58.9%). Only eight surveys among healthcare workers (doctors and nurses) were found, with vaccine acceptance rates ranging from 27.7% in the Democratic Republic of the Congo to 78.1% in Israel. In the majority of survey studies among the general public stratified per country (29/47, 62%), the acceptance of COVID-19 vaccination showed a level of ≥70%. Low rates of COVID-19 vaccine acceptance were reported in the Middle East, Russia, Africa and several European countries. This could represent a major problem in the global efforts to control the current COVID-19 pandemic. More studies are recommended to address the scope of COVID-19 vaccine hesitancy. Such studies are particularly needed in the Middle East and North Africa, Sub-Saharan Africa, Eastern Europe, Central Asia, Middle and South America. Addressing the scope of COVID-19 vaccine hesitancy in various countries is recommended as an initial step for building trust in COVID-19 vaccination efforts.

Keywords: vaccine hesitancy; vaccine acceptance; anti-vaccination; vaccination coverage rates; COVID-19; coronavirus; SARS-CoV-2; vaccine rejection

1. Introduction

Based on the Strategic Advisory Group of Experts on Immunization (SAGE), vaccine hesitancy is the term used to describe: “delay in acceptance or refusal of vaccination despite availability of vaccination services” [1]. Factors that affect the attitude towards acceptance of vaccination include complacency, convenience and confidence [1,2]. Complacency denotes the low perception of the disease risk; hence, vaccination was deemed unnecessary. Confidence refers to the trust in vaccination safety, effectiveness, besides the competence of the healthcare systems. Convenience entails the availability, affordability and delivery of vaccines in a comfortable context [2].

The complex nature of motives behind vaccine hesitancy can be analysed using the epidemiologic triad of environmental, agent and host factors [3,4]. Environmental factors include public health policies, social factors and the messages spread by the media [5–7]. The
agent (vaccine and disease) factors involve the perception of vaccine safety and effectiveness, besides the perceived susceptibility to the disease [7–9]. Host factors are dependent on knowledge, previous experience, educational and income levels [4,10].

Previous studies have shown that vaccine hesitancy is a common phenomenon globally, with variability in the cited reasons behind refusal of vaccine acceptance [11–13]. The most common reasons included: perceived risks vs. benefits, certain religious beliefs and lack of knowledge and awareness [14–16]. The aforementioned reasons can be applied to COVID-19 vaccine hesitancy, as shown by the recent publications that showed a strong correlation between intent to get coronavirus vaccines and its perceived safety [17], association of the negative attitude towards COVID-19 vaccines and unwillingness to get the vaccines [18], and the association of religiosity with lower intention to get COVID-19 vaccines [19].

Studying the global impact of vaccine hesitancy—including willingness to accept COVID-19 vaccines—could be complicated by the multifaceted nature of this phenomenon [1]. This entails the existence of cognitive, psychologic, socio-demographic and cultural factors that contribute to vaccine hesitancy [20–23]. Analysis of such factors is needed to address COVID-19 vaccine hesitancy, following the assessment of the scope and magnitude of this public health threat [24]. This can help in guiding interventional measures aimed at building and maintaining responses to tackle this threat [25].

Earlier studies that assessed attitudes towards vaccines revealed the existence of regional variability in perceiving the safety and effectiveness of vaccination [12,26,27]. Higher-income regions were the least certain regarding vaccine safety with 72%–73% of people in Northern America and Northern Europe who agreed that vaccines are safe. This rate was even lower in Western Europe (59%), and in Eastern Europe (50%), despite the presence of a substantial variability in Eastern European countries (from 32% in Ukraine, 48% in Russia, to 77% in Slovakia). However, the majority of people in lower-income areas agreed that vaccines are safe, with the highest proportions seen in South Asia (95%) and in Eastern Africa (92%) [26]. A similar pattern was observed regarding vaccine effectiveness, with Eastern Europe as the region where people are the least likely to agree that vaccines are effective, as opposed to South Asia and Eastern Africa [26]. The assessment of such regional differences can be invaluable in addressing and fighting public health threats posed by vaccine hesitancy [28].

The current coronavirus disease 2019 (COVID-19) pandemic does not seem to show any signs of decline, with more than 1.7 million deaths and more than 80 million reported cases worldwide, as of 27 December 2020 [29,30]. The ebb and flow of COVID-19 cases can be driven by human factors, including attitude towards physical distancing and protective measures, while viral factors are driven by mutations that commonly occur in severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) genome [31–37]. The viral factors can particularly be of high relevance considering the recent reports of resurgence in COVID-19 infections in UK due to a new variant of the virus [38].

The global efforts to lessen the effects of the pandemic, and to reduce its health and socio-economic impact, rely to a large extent on the preventive efforts [39,40]. Thus, huge efforts by the scientific community and pharmaceutical industry backed by governments’ support, were directed towards developing efficacious and safe vaccines for SARS-CoV-2 [41]. These efforts were manifested by the approval of several vaccines for emergency use, in addition to more than 60 vaccine candidates in clinical trials. Moreover, more than 170 COVID-19 vaccine candidates are in the pre-clinical phase [42].

Despite the huge efforts made to achieve successful COVID-19 vaccines, a major hindrance can be related to vaccine hesitancy towards the approved and prospective COVID-19 vaccination [43]. To identify the scope of this problem, this systematic review aimed to assess the acceptance rates for COVID-19 vaccine(s) in different countries worldwide, which can provide an initial step to study the factors implicated in regional and cultural differences behind COVID-19 vaccine hesitancy.
2. Materials and Methods

This review was conducted following the PRISMA guidelines [44]. Published papers in PubMed/ Medline that aimed at evaluating COVID-19 vaccine hesitancy/vaccine acceptance using a survey/ questionnaire were eligible for inclusion in this review.

Only studies in English language that met the inclusion criteria were considered in this review. The inclusion criteria were: (1) peer-reviewed published articles indexed in PubMed; (2) survey studies among the general population, health-care workers, students, or parents/guardians; (3) the major aim of the study was to evaluate COVID-19 vaccine acceptance/hesitancy; and (4) publication language was English.

The exclusion criteria were: (1) unpublished manuscripts (preprints); (2) the article did not aim to evaluate COVID-19 vaccine acceptance/hesitancy; and (3) publication language was not English.

A search was done as of 25 December 2020, using the following strategy: (COVID * vaccine * hesitancy [Title/Abstract]) OR (COVID * vaccine acceptance [Title/Abstract]) OR (COVID * vaccine * hesitancy *[Title/Abstract])) OR (COVID * intention to vaccine *[Title/Abstract]) OR (COVID* vaccine * accept *[Title/Abstract]) AND (2020:2020[pdat]).

Screening of titles and abstracts was conducted, followed by data extraction for the following items: date of survey, country/countries in which the survey was conducted, target population for survey (e.g., general public, healthcare workers, and students), total number of respondents, and COVID-19 vaccine acceptance rate (which included the number of respondents who answered: agree/somewhat/completely agree/leaning towards yes/definitely yes).

3. Results

A total of 178 records were identified, and following the screening process, a total of 30 articles were included in this review (Figure 1). In addition, data collected in a recently published article that surveyed the general public residing in Jordan and Kuwait were added to the final analysis [45].

![Flow chart of the study selection process.](image)

3.1. Characteristics of the Papers Included in This Review

A total of 30 published papers were analysed in this review, with an additional recently published article that focused on COVID-19 vaccine acceptance in Jordan and Kuwait to yield a total of 31 studies. These studies comprised surveys on COVID-19 vaccine acceptance from a total of 33 different countries. Surveys were done most commonly in the UK (n = 6), followed by France and the US (n = 5, for each country), and China and Italy.
(n = 4, for each country). Dates of survey distribution ranged from February 2020 until December 2020. A few studies were conducted in more than one country, including the study by Lazarus et al., involving 19 countries and the study by Neumann-Böhme et al., involving seven European countries [46,47].

Stratified per country, a total of 60 surveys were found with the largest sample size (n = 5114) in the study conducted in the UK by Freeman et al., while the smallest sample size (n = 123) was found in the study conducted in Malta by Gretch et al., among general practitioners and trainees [48,49]. Out of these 60 surveys, 47 were among the general public, eight surveys were among healthcare workers (doctors, nurses, or others), three surveys were among parents/guardians and two surveys involved University students (Table 1). Surveys were most commonly conducted in June or July (23/60, 38%), followed by March or April (20/60, 33%).

**Table 1.** COVID-19 acceptance rates divided by the included studies and sorted based on the date of survey.

| Study | Country | Date of Survey | Response Recorded as Vaccine Acceptance | N | Target Population | Acceptance Rate (%) | Age/sex Correlation with Higher Vaccine Acceptance |
|-------|---------|----------------|----------------------------------------|---|-------------------|------------------|-----------------------------------------------|
| Wang et al. [50] | Hong Kong | February and March, 2020 | Intend to accept | 806 | Nurses | 40.0 | Male |
| Wang et al. [51] | China | March, 2020 | Yes | 2058 | General population | 91.3 | Male |
| Harapan et al. [52] | Indonesia | March and April 2020 | Yes | 1359 | General population | 93.3 | None |
| Dror et al. [53] | Israel | March and April 2020 | Yes | 388 | Doctors | 78.1 | - |
| Detoc et al. [54] | France | March and April 2020 | Yes certainly/possibly | 3259 | General population | 77.6 | Male, age |
| Dror et al. [53] | Israel | March and April 2020 | Yes | 1112 | General population | 75.0 | - |
| Kwok et al. [55] | Hong Kong | March and April 2020 | Likely to vaccinate (scored 6 or above out of 10) | 1205 | Nurses | 63.0 | Age |
| Dror et al. [53] | Israel | March and April 2020 | Yes | 211 | Nurses | 61.1 | - |
| Nzaji et al. [56] | DRC 2 | March and April 2020 | Yes | 613 | Healthcare workers | 27.7 | Age |
| Gagneux-Brunon et al. [57] | France | March to July, 2020 | Yes | 2047 | Healthcare workers | 76.9 | Male, age |
| Sarasty et al. [58] | Ecuador | April, 2020 | Willing to accept a vaccine | 1050 | General population | 97.0 | - |
| Wong et al. [59] | Malaysia | April, 2020 | Definitely, probably or possibly yes | 1159 | General population | 94.3 | Male |
| Neumann-Böhme et al. [47] 1 | Denmark | April, 2020 | Yes | 1000 | General population | 80.0 | - |
| Neumann-Böhme et al. [47] 2 | UK 3 | April, 2020 | Yes | 1000 | General population | 79.0 | - |
| Neumann-Böhme et al. [47] | Italy | April, 2020 | Yes | 1500 | General population | 77.3 | - |
| Ward et al. [60] | France | April and May 2020 | Certainly or probably | 5018 | General population | 76.0 | None |
| Neumann-Böhme et al. [47] | Portugal | April, 2020 | Yes | 1000 | General population | 75.0 | - |
| Neumann-Böhme et al. [47] | Netherland | April, 2020 | Yes | 1000 | General population | 73.0 | - |
| Neumann-Böhme et al. [47] | Germany | April, 2020 | Yes | 1000 | General population | 70.0 | - |
| Neumann-Böhme et al. [47] | France | April, 2020 | Yes | 1000 | General population | 62.0 | - |
| Fisher et al. [61] | US 4 | April, 2020 | Yes | 1003 | General population | 56.9 | Male, age |
| Salali & Uysal [62] | UK | May, 2020 | Yes | 1088 | General population | 83.0 | None |
| Study                  | Country  | Date of Survey | Response Recorded as Vaccine Acceptance | N 6   | Target Population     | Acceptance Rate (%) | Age/Church Correlation with Higher Vaccine Acceptance |
|-----------------------|----------|----------------|------------------------------------------|-------|-----------------------|---------------------|-------------------------------------------------------|
| Lin et al. [63]        | China    | May, 2020      | Definitely/probably yes                   | 3541  | General population     | 83.5                | None                                                  |
| Taylor et al. [64]     | Canada   | May, 2020      | Yes                                       | 1902  | General population     | 80.0                | Male, age                                             |
| Taylor et al. [64]     | US       | May, 2020      | Yes                                       | 1772  | General population     | 75.0                | Male, age                                             |
| Salali & Uysal [62]    | Turkey   | May, 2020      | Yes                                       | 3936  | General population     | 66.0                | Male                                                  |
| Reiter et al. [65]     | US       | May, 2020      | Definitely/probably willing                | 2006  | General population     | 68.5                | Male                                                  |
| Malik et al. [66]      | US       | May, 2020      | Agree/strongly agree                       | 672   | General population     | 67.0                | Male, age                                             |
| Lazarus et al. [46]    | India    | June, 2020     | Completely/somewhat agree                 | 712   | General population     | 88.6                | -                                                     |
| Barello et al. [67]    | Italy    | June, 2020     | Yes                                       | 735   | University students    | 86.1                | -                                                     |
| Lazarus et al. [46]    | Brazil   | June, 2020     | Completely/somewhat agree                 | 717   | General population     | 85.4                | -                                                     |
| Lazarus et al. [46]    | South Africa | June, 2020   | Completely/somewhat agree                 | 619   | General population     | 81.6                | -                                                     |
| Lazarus et al. [46]    | South Korea | June, 2020    | Completely/somewhat agree                 | 752   | General population     | 79.8                | -                                                     |
| Lazarus et al. [46]    | Mexico   | June, 2020     | Completely/somewhat agree                 | 699   | General population     | 76.3                | -                                                     |
| Lazarus et al. [46]    | US       | June, 2020     | Completely/somewhat agree                 | 773   | General population     | 75.4                | -                                                     |
| Lazarus et al. [46]    | India    | June, 2020     | Completely/somewhat agree                 | 742   | General population     | 74.5                | -                                                     |
| Lazarus et al. [46]    | Spain    | June, 2020     | Completely/somewhat agree                 | 748   | General population     | 74.3                | -                                                     |
| Lazarus et al. [46]    | Ecuador  | June, 2020     | Completely/somewhat agree                 | 741   | General population     | 71.9                | -                                                     |
| Lazarus et al. [46]    | UK       | June, 2020     | Completely/somewhat agree                 | 768   | General population     | 71.5                | -                                                     |
| Lazarus et al. [46]    | Italy    | June, 2020     | Completely/somewhat agree                 | 736   | General population     | 70.8                | -                                                     |
| Lazarus et al. [46]    | Canada   | June, 2020     | Completely/somewhat agree                 | 707   | General population     | 68.7                | -                                                     |
| Lazarus et al. [46]    | Germany  | June, 2020     | Completely/somewhat agree                 | 722   | General population     | 68.4                | -                                                     |
| Lazarus et al. [46]    | Singapore| June, 2020     | Completely/somewhat agree                 | 655   | General population     | 67.9                | -                                                     |
| Lazarus et al. [46]    | Sweden   | June, 2020     | Completely/somewhat agree                 | 650   | General population     | 65.2                | -                                                     |
| Lazarus et al. [46]    | Nigeria  | June, 2020     | Completely/somewhat agree                 | 670   | General population     | 65.2                | -                                                     |
| Lazarus et al. [46]    | France   | June, 2020     | Completely/somewhat agree                 | 669   | General population     | 58.9                | -                                                     |
| Lazarus et al. [46]    | Poland   | June, 2020     | Completely/somewhat agree                 | 666   | General population     | 56.3                | -                                                     |
| Lazarus et al. [46]    | Russia   | June, 2020     | Completely/somewhat agree                 | 680   | General population     | 54.9                | -                                                     |
| Rhodes et al. [68]     | Australia| June, 2020     | Yes                                       | 2018  | Parents and guardians  | 75.8                | Male, age                                             |
| Bell et al. [69]       | UK       | July, 2020     | Yes, definitely or unsure but leaning towards yes | 1252  | Parents and guardians  | 89.1                | -                                                     |
Table 1. Cont.

| Study                        | Country       | Date of Survey     | Response Recorded as Vaccine Acceptance | N  | Target Population | Acceptance Rate (%) | Age/Sex Correlation with Higher Vaccine Acceptance |
|------------------------------|---------------|--------------------|-----------------------------------------|----|-------------------|---------------------|--------------------------------------------------|
| Sherman et al. [70]          | UK            | July, 2020         | Very likely                             | 1500 | General population | 64.0                | Age                                              |
| Zhang et al. [71]            | China         | September, 2020    | Likely or very likely                   | 1052 | Parents and guardians | 72.6               | None                                             |
| Gretch et al. [49]           | Malta         | September, 2020    | Likely                                  | 123  | GPs and GP trainees | 61.8                | -                                                |
| La Vecchia et al. [72]       | Italy         | September, 2020    | Yes/probably yes                         | 1055 | General population | 53.7                | -                                                |
| Gretch et al. [73]           | Malta         | September, 2020    | Likely                                  | 1002 | Healthcare workers | 52.0                | -                                                |
| Gretch & Gauci [74]          | Malta         | September, 2020    | Likely                                  | 852  | University students/staff | 44.2               | -                                                |
| Freeman et al. [48]          | UK            | September and October, 2020 | Endorsing 4/7 items of Oxford Scale 5 | 5114 | General population | 71.7                | Male, age                                        |
| Al-Mohaithef & Badhi [75]    | Saudi Arabia  | Unknown            | Yes                                     | 992  | General population | 64.7                | None                                             |
| Sallam et al. [45]           | Jordan        | December, 2020     | Yes                                     | 2173 | General population | 28.4                | Male                                             |
| Sallam et al. [45]           | Kuwait        | December, 2020     | Yes                                     | 771  | General population | 23.6                | Male                                             |

1 The study by Neumann-Böhme et al. reported that males and participants > 55 years were more willing to accept COVID-19 vaccines; however, this finding was not stratified per country.
2 DRC: The Democratic Republic of the Congo; 3 UK: United Kingdom; 4 US: United States; 5 Oxford Scale: Oxford COVID-19 vaccine hesitancy scale developed by Freeman et al. [48]; 6 N: Number.

3.2. Rates of COVID-19 Vaccine Acceptance

The results of the COVID-19 vaccine acceptance rates in different studies included in this review and stratified by country are shown in Table 1. Classified per study, the highest vaccine acceptance rates (>90%) among the general public were found in four studies from Ecuador (97.0%), Malaysia (94.3%), Indonesia (93.3%) and China (91.3%). On the contrary, the lowest vaccine acceptance rates (<60%) among the general public were found in seven studies to be from Kuwait (23.6%), Jordan (28.4%), Italy (53.7), Russia (54.9%), Poland (56.3%), US (56.9%), and France (58.9%). In Figure 2, COVID-19 vaccine acceptance rates are shown per country, with the latest estimate used for countries with multiple studies.
For the eight studies conducted on healthcare workers, three surveys reported vaccine acceptance rates below 60%, with the highest rate being among doctors in Israel (78.1%) and the lowest vaccine acceptance rate (27.7%) reported among healthcare workers in the Democratic Republic of the Congo (DRC).

For the three studies conducted among parents/guardians, the vaccine acceptance rates were more than 70%. For the two studies among University students, the vaccine acceptance rate was 57.3% in Malta (excluding university staff), and 86.1% in Italy.

Male sex was associated with significantly higher rates of COVID-19 vaccine in 15 countries/studies, while the age was a significant factor in 11 studies/countries.
3.3. Changes in COVID-19 Vaccine Acceptance over Time in Countries with Multiple Survey Studies

In countries with multiple surveys over time, the following changes in COVID-19 vaccine acceptance rates were observed. In the UK, the vaccine acceptance rate was 79.0% in April, 83.0% in May, 71.5% in June, 64.0% in July and 71.7% in September/October. In France, the vaccine acceptance rate ranged from 62.0% to 77.1% in March/April and was 58.9% in June. In Italy, the vaccine acceptance rate was 77.3% in April, 70.8% in June and it reached 53.7% in September.

For the vaccine acceptance rates in the US, it was 56.9% in April, and ranged from 67.0% to 75.0% in May, and reached 75.4% in June. In China, three studies reported high rates of vaccine acceptance with the first study that reported a vaccine acceptance rate of 91.3% in March, the second study reported a rate of 83.5% in May and the third study reported a rate of 88.6% in June.

4. Discussion

Vaccine hesitancy is an old phenomenon that represents a serious threat to the global health, as shown by the resurgence of some infectious diseases (e.g., outbreaks of measles and pertussis) [76–80]. The huge leaps in developing efficacious and safe COVID-19 vaccines within a short period were unprecedented [81–83]. Nevertheless, COVID-19 vaccine hesitancy can be the limiting step in the global efforts to control the current pandemic with its negative health and socio-economic effects [43,84,85].

Assessing the level of population immunity necessary to limit the pathogen spread is dependent on the basic reproductive number for that infectious disease [86]. The latest estimates on COVID-19, pointed out a range of 60–75% immune individuals that would be necessary to halt the forward transmission of the virus and community spread of the virus [87–89]. Vaccine cost, effectiveness and duration of protection appear as important factors to achieve such a goal [83,90,91]. However, vaccine hesitancy can be a decisive factor that would hinder the successful control of the current COVID-19 pandemic [43,92]. Thus, estimates of vaccine acceptance rates can be helpful to plan actions and intervention measures necessary to increase the awareness and assure people about the safety and benefits of vaccines, which in turn would help to control virus spread and alleviate the negative effects of this unprecedented pandemic [93,94]. Evaluation of attitudes and acceptance rates towards COVID-19 vaccines can help to initiate communication campaigns that are much needed to strengthen trust in health authorities [24].

In this review, a large variability in COVID-19 vaccine acceptance rates was found. However, certain patterns can be deduced based on descriptive analysis of the reported vaccine acceptance rates. First, in East and South East Asia, the overall acceptance rates among the general public were relatively high. This includes more than 90% acceptance rates in Indonesia, Malaysia and one study from China [51,52,59]. Another two surveys on the general public in China reported vaccine acceptance rates of more than 80%, with an additional survey in South Korea that reported a rate of 79.8% [46,63]. A later survey from Shenzhen, China, by Zhang et al., which surveyed parents/guardians who were factory workers, on their acceptability of children COVID-19 vaccination reported a lower rate of 72.5% compared to previous studies [71]. Similarly, an online survey on Australian parents showed an acceptance rate of 75.8%, dropping from a rate of 85.8% in April among adults in Australia who were surveyed in April 2020 [68,95]. The lowest COVID-19 vaccine acceptance rate among the general public in the region was reported by Lazarus et al., in Singapore (67.9%) [46]. The relatively high rates of vaccine acceptance in the region were attributed to strong trust in governments [46]. Additionally, the only survey in India reported a vaccine acceptance rate of 74.5% [46]. The relatively high rates of COVID-19 vaccine acceptance might be related to stronger confidence in vaccine safety and effectiveness, as reported previously in Asia [27].

However, two studies that dated back to the early part of the pandemic (February and March) among nurses in Hong Kong reported low rates of COVID-19 acceptance
Vaccines 2021, 9, 160

Likewise, Kabamba Nzaji et al. reported a very low rate of COVID-19 vaccine acceptance among healthcare workers in the DRC (27.7%) [56]. This issue is alarming considering the front-line position of healthcare workers in fighting the spread and effects of the COVID-19 pandemic, which put them at a higher risk of infection, and hence their higher need for protective measures [96–98].

Additionally, the vaccine acceptance rates were relatively high in Latin America, where results from Brazil and Ecuador reported more than 70% acceptance rates [46,58]. This was also seen in the survey from Mexico with a vaccine acceptance rate of 76.3% [46].

In Europe, the results were largely variable, with countries around the Mediterranean reporting vaccine acceptance rates as low as 53.7% in Italy, and 58.9% in France; no surveys among the general public in Malta were found [46,72]. The results in Italy and France can be viewed from the perspective of lacking confidence in the safety of these vaccines, since such a negative attitude was reported previously in these countries [27]. In addition, low rates of COVID-19 vaccine acceptance were reported among students and healthcare workers in Malta—44.2% and 52.0%, respectively [73,74]. Variable results were also reported in other European countries with rates as high as 80.0% in Denmark, and as low as 56.3% in Poland [46,47]. The vaccine acceptance rates were even lower in Russia (54.9%), which needs further evaluation considering the heavy toll of COVID-19 on the country [29,46]. Variability in vaccine acceptance rates was also seen in the UK, US and Canada over the course of the pandemic [61,62,64,65,70]. Additionally, a drop in COVID-19 vaccine acceptance was noticed in a few European countries, which is in line with the recent report by Lin et al. [24]. Such patterns of COVID-19 vaccine hesitancy were consistent with a previous report that showed relatively high rates of vaccine hesitancy in Western and Eastern Europe, in addition to Russia [26]. The aforementioned low rates can be linked to lower confidence in vaccine safety and effectiveness in these regions [26].

The Middle East was among the regions with the lowest COVID-19 vaccine acceptance rates globally. The acceptance rate was the lowest in Kuwait (23.6%), followed by Jordan (28.4%), Saudi Arabia (64.7%) and Turkey (66.0%) [45,62,75]. Such low rates can be related to the widespread embrace of conspiratorial beliefs in the region, with its subsequent negative attitude towards vaccination [23,99–101]. However, the highest vaccine acceptance rate was reported in Israel (75.0%); however, this rate was much lower among nurses surveyed in the same study (61.1%) [53].

Only two surveys among the general public in African countries reported an acceptance rate of 81.6% in South Africa and 65.2% in Nigeria [46]. Early knowledge, attitudes and practices survey study towards COVID-19, from North-Central Nigeria, reported an acceptance rate of barely 29.0%, which highlights the need for more studies for an accurate depiction of COVID-19 vaccine hesitancy in Africa due to possible large regional and sub-regional variations [102]. Thus, more studies are recommended in Africa to address COVID-19 vaccine hesitancy in the continent. Despite the previous findings of an overall low prevalence of vaccine hesitancy in Eastern Africa, the attitude towards the newer vaccines, including those of COVID-19, remains a study topic that has not been explored to a large degree [12].Besides Africa, more studies are needed from Central Asia, Eastern Europe, Central and South America to reach reliable conclusions about the scope of COVID-19 vaccine hesitancy around the globe.

Finally, the assessment of the role of sex and age in COVID-19 vaccine hesitancy revealed that males were more inclined to accept COVID-19 vaccines. This can be related to their higher perception of COVID-19 dangers and lower belief in conspiratorial claims surrounding the disease [45,99,101]. These variables should be considered for an accurate interpretation of COVID-19 acceptance rates, since sampling bias, particularly in sex distribution, can affect the reported rates.

The limitations of this review include the sole dependence on PubMed in the search study; however, this approach was done to provide a concise and succinct evaluation of COVID-19 vaccine hesitancy. This approach could have resulted in the inevitable missing of a few relevant studies tackling the subject of this review (e.g., the study by Head et al.
assessing SARS-CoV-2 vaccination intentions among adults in the US) [103]. In addition, the research studies included in this review represented cross-sectional studies, which can be seen as snapshots of vaccine hesitancy status in each country/region, with different sampling strategies, which may partly explain the differences in vaccine acceptance rates reported in various studies from a single country. Thus, the results should be interpreted with extreme caution since they cannot predict the future changes in vaccine acceptance rates. The results of this study can be used as an initial motivation and guide for future studies and vaccine awareness campaigns. Finally, an important limitation was related to the different approaches used to express the willingness to accept COVID-19 vaccines in various studies (i.e., some studies used a binary response of yes/no, while others used a scale of strongly agree/agree/neutral/disagree/strongly disagree to deduce the inclination towards vaccine acceptance, etc.); thus, this variable should be taken into account for accurate comparisons of vaccine acceptance rates between different studies.

5. Conclusions

Large variability in COVID-19 vaccine acceptance rates was reported in different countries and regions of the world. A sizable number of studies reported COVID-19 acceptance rates below 60%, which would pose a serious problem for efforts to control the current COVID-19 pandemic. Low COVID-19 vaccine acceptance rates were more pronounced in the Middle East, Eastern Europe and Russia. High acceptance rates in East and South East Asia would help to achieve proper control of the pandemic. More studies are recommended to assess the attitude of general public and healthcare workers in Africa, Central Asia and the Middle East besides Central and South America. Such studies would help to evaluate COVID-19 vaccine hesitancy and its potential consequences in these regions, and around the globe.

The major challenges that could face successful implementation of COVID-19 vaccination programs to fight the unprecedented pandemic include mass manufacturing of vaccines, its fair distribution across the world and the uncertainty regarding its long-term efficacy. However, vaccine hesitancy can be the major hindrance of the control efforts to lessen the negative consequences of COVID-19 pandemic, at least in certain countries/regions.

The widespread prevalence of COVID-19 vaccine hesitancy mandates collaborative efforts of governments, health policy makers, and media sources, including social media companies. It is recommended to build COVID-19 vaccination trust among the general public, via the spread of timely and clear messages through trusted channels advocating the safety and efficacy of currently available COVID-19 vaccines.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical approval is not applicable for this systematic review since data from previous published studies in which informed consent was obtained by primary investigators was analyzed.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data supporting this systematic review are available in the reference section. In addition, the analyzed data that were used during the current systematic review are available from the author on reasonable request.

Acknowledgments: I wish to express my sincere gratitude for the reviewers, for their insightful and valuable comments on the manuscript that helped to improve its quality to a great degree.

Conflicts of Interest: The author declares no conflict of interest.
Vaccines 2021, 9, 160

References

1. MacDonald, N.E.; Sage Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [CrossRef]

2. SAGE Working Group on Vaccine Hesitancy. Report of the SAGE Working Group on Vaccine Hesitancy. Available online: https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf (accessed on 26 December 2020).

3. Gowda, C.; Dempsey, A.F. The rise (and fall?) of parental vaccine hesitancy. Hum. Vaccines Immunother. 2013, 9, 1755–1762. [CrossRef]

4. Kumar, D.; Chandra, R.; Mathur, M.; Samdariya, S.; Kapoor, N. Vaccine hesitancy: Understanding better to address better. Isr. J. Health Policy Res. 2016, 5, 2. [CrossRef]

5. Daley, M.F.; Narwaney, K.J.; Shoup, J.A.; Wagner, N.M.; Glanz, J.M. Addressing Parents’ Vaccine Concerns: A Randomized Trial of a Social Media Intervention. Am. J. Prev. Med. 2018, 55, 44–54. [CrossRef]

6. Arede, M.; Bravo-Araya, M.; Bouchard, E.; Singh Gill, G.; Plajer, V.; Shehraj, A.; Adam Shuaib, Y. Combating Vaccine Hesitancy: Teaching the Next Generation to Navigate Through the Post Truth Era. Front. Public Health 2018, 6, 381. [CrossRef]

7. Dube, E.; Vivion, M.; MacDonald, N.E. Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: Influence, impact and implications. Expert Rev. Vaccines 2015, 14, 99–117. [CrossRef] [PubMed]

8. Salmon, D.A.; Dudley, M.Z.; Glanz, J.M.; Omer, S.B. Vaccine Hesitancy: Causes, Consequences, and a Call to Action. Am. J. Prev. Med. 2015, 49, S91–S98. [CrossRef] [PubMed]

9. Larson, H.J.; Cooper, L.Z.; Eskola, J.; Katz, S.L.; Ratzan, S. Addressing the vaccine confidence gap. Lancet 2011, 378, 526–535. [CrossRef]

10. Olson, O.; Berry, C.; Kumar, N. Addressing Parental Vaccine Hesitancy towards Childhood Vaccines in the United States: A Systematic Literature Review of Communication Interventions and Strategies. Vaccines 2020, 8, 590. [CrossRef] [PubMed]

11. Lane, S.; MacDonald, N.E.; Marti, M.; Dumolard, L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017. Vaccine 2018, 36, 3861–3867. [CrossRef]

12. Wagner, A.L.; Masters, N.B.; Domek, G.J.; Mathew, J.L.; Sun, X.; Asturias, E.J.; Ren, J.; Huang, Z.; Contreras-Roldan, I.L.; Gebremeskel, B.; et al. Comparisons of Vaccine Hesitancy across Five Low- and Middle-Income Countries. Vaccines 2019, 7, 155. [CrossRef]

13. The Lancet Child & Adolescent Health. Vaccine hesitancy: A generation at risk. Lancet Child Adolesc. Health 2019, 3, 281. [CrossRef]

14. Karaffillakis, E.; Larson, H.J.; Consortium, A. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine 2017, 35, 4840–4850. [CrossRef]

15. Pelcic, G.; Karacic, S.; Mikirtichan, G.L.; Kubar, O.I.; Leavitt, F.J.; Cheng-Tek Tai, M.; Morishita, N.; Vuletic, S.; Tomasevic, L. Religious exception for vaccination or religious excuses for avoiding vaccination. Croat. Med. J. 2016, 57, 516–521. [CrossRef]

16. Yaqub, O.; Castle-Clarke, S.; Sevdalis, N.; Chataway, J. Attitudes to vaccination: A critical review. Soc. Sci. Med. 2014, 112, 1–11. [CrossRef]

17. Karlsson, L.C.; Soveri, A.; Lewandowsky, S.; Karlsson, L.; Karlsson, H.; Nolvi, S.; Karukivi, M.; Lindfelt, M.; Antfolk, J. Fearing the disease or the vaccine: The case of COVID-19. Personal. Individ. Differ. 2021, 172, 110590. [CrossRef]

18. Paul, E.; Steptoe, A.; Fancourt, D. Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications. Lancet Reg. Health Eur. 2021, 1, [CrossRef]

19. Olagoke, A.A.; Olagoke, O.O.; Hughes, A.M. Intention to Vaccinate Against the Novel 2019 Coronavirus Disease: The Role of Health Locus of Control and Religion. J. Relig. Health. 2020, [CrossRef] [PubMed]

20. Murphy, J.; Vallieres, F.; Bentall, R.P.; Shevlin, M.; McBride, O.; Hartman, T.K.; McKay, R.; Bennett, K.; Mason, L.; Gibson-Miller, J.; et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat. Commun. 2021, 12, 29. [CrossRef] [PubMed]

21. Pomares, T.D.; Buttenheim, A.M.; Buttenheim, A.M.; Porter, R.M.; Bednarczyk, R.A.; Omer, S.B. Association of cognitive biases with human papillomavirus vaccine hesitancy: A cross-sectional study. Hum. Vaccines Immunother. 2018, 14, 4161–4164. [CrossRef] [PubMed]

22. Browne, M.; Thomson, P.; Rockloff, M.J.; Pennycook, G. Going against the Herd: Psychological and Cultural Factors Underlying the ‘Vaccination Confidence Gap’. PLoS ONE 2015, 10, e0132562. [CrossRef]

23. Hornsey, M.J.; Harris, E.A.; Fielding, K.S. The psychological roots of anti-vaccination attitudes: A 24-nation investigation. Health Psychol. 2018, 37, 307–315. [CrossRef]

24. Lin, C.; Tu, P.; Beitsch, L.M. Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. Vaccines 2021, 9, 16. [CrossRef]

25. de Figueiredo, A.; Simas, C.; Karaffillakis, E.; Paterson, P.; Larson, H.J. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: A large-scale retrospective temporal modelling study. Lancet 2020, 396, 898–908. [CrossRef]

26. Welcome Global Monitor. How Does the World Feel about Science and Health? Available online: https://wellcome.org/sites/default/files/wellcome-global-monitor-2018.pdf (accessed on 9 February 2021).

27. Larson, H.J.; de Figueiredo, A.; Xiaohong, Z.; Schulz, W.S.; Verger, F.; Johnston, I.G.; Cook, A.R.; Jones, N.S. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine 2016, 12, 295–301. [CrossRef]
28. The All-Party Parliamentary Group (APPG) on Vaccinations for All. The Next Decade of Vaccines: Addressing the Challenges That Remain towards Achieving Vaccinations for All. Available online: https://www.results.org.uk/sites/default/files/files/NextDecadeOfVaccines_Single_NoBleed.pdf (accessed on 9 February 2021).

29. Worldometer. COVID-19 Coronavirus Pandemic. Available online: https://www.worldometers.info/coronavirus/ (accessed on 10 January 2021).

30. World Health Organization. COVID-19 Weekly Epidemiological Update, 22 December 2020. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update---22-december-2020 (accessed on 26 December 2020).

31. Prem, K.; Liu, Y.; Russell, T.W.; Kucharski, A.J.; Eggo, R.M.; Davies, N.; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Jit, M.; Klepac, P. The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: A modelling study. Lancet Public Health 2020, 5, e261–e270. [CrossRef]

32. Viner, R.M.; Russell, S.J.; Croker, H.; Packer, J.; Ward, J.; Stansfield, C.; Myton, O.; Bonell, C.; Booy, R. School closure and management practices during coronavirus outbreaks including COVID-19: A rapid systematic review. Lancet Child Adolesc. Health 2020, 4, 397–404. [CrossRef]

33. Dong, S.; Shen, C.; Xia, N.; Song, W.; Fan, M.; Cowling, B.J. Rational use of face masks in the COVID-19 pandemic. Lancet Respir. Med. 2020, 8, 434–436. [CrossRef]

34. Korber, B.; Fischer, W.M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E.E.; Bhattacharya, T.; Foley, B. Tracking changes in SARS-CoV-2 Spike: Evidence that D614G increases infectivity of the COVID-19 virus. Cell 2020, 182, 812–827.e19. [CrossRef]

35. Grubaugh, N.D.; Hanage, W.P.; Rasmussen, A.L. Making sense of mutation: What D614G means for the COVID-19 pandemic remains unclear. Cell 2020, 182, 794–795. [CrossRef]

36. Sallam, M.; Ababneh, N.A.; Dababseh, D.; Bakri, F.G.; Mahafzah, A. Temporal increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa. Helyox 2021, 7, e06035. [CrossRef]

37. Wise, J. Covid-19: New Coronavirus Variant Is Identified in UK; British Medical Journal Publishing Group: London, UK, 2020. [CrossRef]

38. European Centre for Disease Prevention and Control. Threat Assessment Brief: Rapid Increase of a SARS-CoV-2 Variant with Multiple Spike Protein Mutations Observed in the United Kingdom. Available online: https://www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-rapid-increase-sars-cov-2-variant-united-kingdom (accessed on 26 December 2020).

39. Nicola, M.; Alsafi, Z.; Sohrabi, C.; Kerwan, A.; Al-Jabir, A.; Iosifidis, C.; Agha, M.; Agha, R. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int. J. Surg. 2020, 78, 185–193. [CrossRef] [PubMed]

40. Calina, D.; Docea, A.O.; Petrakis, D.; Egorov, A.M.; Ishmukhametov, A.A.; Gabibov, A.G.; Shtilman, M.I.; Kostoff, R.; Carvalho, F.; Vinceti, M.; et al. Towards effective COVID19 vaccines: Updates, perspectives and challenges (Review). Int. J. Mol. Med. 2020, 46, 3–16. [CrossRef] [PubMed]

41. Conte, C.; Sogni, F.; Affanni, P.; Veronesi, L.; Argentiero, A.; Esposito, S. Vaccines against Coronaviruses: The State of the Art. Vaccines 2020, 8, 309. [CrossRef]

42. World Health Organization (WHO). Draft Landscape of COVID-19 Candidate Vaccines. Available online: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed on 26 December 2020).

43. Harrison, E.A.; Wu, J.W. Vaccine confidence in the time of COVID-19. Eur. J. Epidemiol. 2020, 35, 325–330. [CrossRef] [PubMed]

44. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [CrossRef]

45. Sallam, M.; Dababseh, D.; Eid, H.; Al-Mahzoum, K.; Al-Haidar, A.; Taim, D.; Yaseen, A.; Ababneh, N.A.; Bakri, F.G.; Mahafzah, A. High rates of COVID-19 vaccine hesitancy and its association with conspiracy beliefs: A study in Jordan and Kuwait among other Arab countries. Vaccines 2021, 9, 42. [CrossRef] [PubMed]

46. Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2020. [CrossRef]

47. Neumann-Böhme, S.; Varghese, N.E.; Sabat, I.; Barros, PP.; Brouwer, W.; van Exel, J.; Schreyögg, J.; Stargardt, T. Once We Have It, Will We Use It? A European Survey on Willingness to Be Vaccinated against COVID-19: Springer: Berlin/Heidelberg, Germany, 2020. [CrossRef]

48. Freeman, D.; Loe, B.S.; Chadwick, A.; Vaccari, C.; Waite, F.; Rosebrock, L.; Jenner, L.; Petit, A.; Lewandowsky, S.; Vanderslott, S.; et al. COVID-19 Vaccine Hesitancy in the UK: The Oxford Coronavirus Explanations, Attitudes, and Narratives Survey (OCEANS) II. Psychol. Med. 2020, 1–34. [CrossRef]

49. Grech, V.; Bonnici, J.; Zammit, D. Vaccine hesitancy in Maltese family physicians and their trainees vis-a-vis influenza and novel COVID-19 vaccination. Early Hum. Dev. 2020, 105259. [CrossRef]

50. Wang, K.; Wong, E.L.Y.; Ho, K.F.; Cheung, A.W.L.; Chan, E.Y.Y.; Yeoh, E.K.; Wong, S.Y.S. Intention of nurses to accept coronavirus disease 2019 vaccination and change of intention to accept seasonal influenza vaccination during the coronavirus disease 2019 pandemic: A cross-sectional survey. Vaccine 2020, 38, 7049–7056. [CrossRef]

51. Wang, J.; Jing, R.; Lai, X.; Zhang, H.; Lyu, Y.; Knoll, M.D.; Fang, H. Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China. Vaccines 2020, 8, 482. [CrossRef]

52. Harapan, H.; Wagner, A.L.; Yufika, A.; Winardi, W.; Anwar, S.; Gan, A.K.; Setiawan, A.M.; Rajamoorthy, Y.; Sofyan, H.; Mudatsir, M. Acceptance of a COVID-19 Vaccine in Southeast Asia: A Cross-Sectional Study in Indonesia. Front. Public Health 2020, 8, 381. [CrossRef]
53. Dror, A.A.; Eisenbach, N.; Taiber, S.; Morozov, N.G.; Mizrachi, M.; Zigron, A.; Srouji, S.; Sela, E. Vaccine hesitancy: The next challenge in the fight against COVID-19. *Eur. J. Epidemiol.* 2020, 35, 775–779. [CrossRef]

54. Detoc, M.; Bruel, S.; Frappe, P.; Tardy, B.; Botelho-Nevers, E.; Gagneux-Brunon, A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. *Vaccine* 2020, 38, 7002–7006. [CrossRef]

55. Kwok, K.O.; Li, K.K.; Wei, W.I.; Tang, A.; Wong, S.Y.S.; Lee, S.S. Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. *Int. J. Nurs. Stud.* 2020, 114, 103854. [CrossRef]

56. Kabamba Nzaji, M.; Kabamba Ngombe, L.; N'goie Mwamba, G.; Banza Ndala, D.B.; Mbidi Miema, J.; Luhatta Lungoyo, C.; Lora Mwimba, B.; Cikomola Mwana Bene, A.; Mukamba Musenga, E. Acceptability of Vaccination Against COVID-19 Among Healthcare Workers in the Democratic Republic of the Congo. *Pragmat. Obs. Res.* 2020, 11, 103–109. [CrossRef]

57. Gagneux-Brunon, A.; Detoc, M.; Bruel, S.; Tardy, B.; Rozaire, O.; Frappe, P.; Botelho-Nevers, E. Intention to get vaccinations against COVID-19 in French healthcare workers during the first pandemic wave: A cross sectional survey. *J. Hosp. Infect.* 2020. [CrossRef]

58. Sarasty, O.; Carpio, C.E.; Hudson, D.; Guerrero-Ochoa, P.A.; Borja, I. The demand for a COVID-19 vaccine in Ecuador. *Vaccine* 2020, 38, 8090–8098. [CrossRef]

59. Wong, L.P.; Alias, H.; Wong, P.F.; Lee, H.Y.; AbuBakar, S. The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay. *Hum. Vaccines Immunother.* 2020, 16, 2204–2214. [CrossRef]

60. Ward, J.K.; Alleaume, C.; Peretti-Watel, P.; Group, C. The French public’s attitudes to a future COVID-19 vaccine: The politicization of a public health issue. *Soc. Sci. Med.* 2020, 265, 113414. [CrossRef] [PubMed]

61. Fisher, K.A.; Bloomstone, S.J.; Walder, J.; Crawford, S.; Fouayzi, H.; Mazor, K.M. Attitudes Toward a Potential SARS-CoV-2 Vaccine: A Survey of U.S. Adults. *Ann. Intern. Med.* 2020, 173, 964–973. [CrossRef]

62. Salali, G.D.; Uysal, M.S. COVID-19 vaccine hesitancy is associated with beliefs on the origin of the novel coronavirus in the UK and Turkey. *Psychol. Med.* 2020, 1–3. [CrossRef]

63. Lin, Y.; Hu, Z.; Zhao, Q.; Alias, H.; Danae, M.; Wong, L.P. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. *PloS Negl. Trop. Dis.* 2020, 14, e0008961. [CrossRef]

64. Taylor, S.; Landry, C.A.; Paluszek, M.M.; Groenewoud, R.; Rachor, G.S.; Asmundson, G.J.G. A Proactive Approach for Managing COVID-19: The Importance of Understanding the Motivational Roots of Vaccination Hesitancy for SARS-CoV2. *Front. Psychol.* 2020, 11, 575950. [CrossRef]

65. Reiter, P.L.; Pennell, M.L.; Katz, M.L. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? *Vaccine* 2020, 38, 6500–6507. [CrossRef]

66. Malik, A.A.; McFadden, S.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine* 2020, 26, 100495. [CrossRef]

67. Barello, S.; Nania, T.; Dellafiore, F.; Graffigna, G.; Caruso, R. ‘Vaccine hesitancy’ among university students in Italy during the COVID-19 pandemic. *Eur. J. Epidemiol.* 2020, 35, 781–783. [CrossRef]

68. Rhodes, A.; Hoq, M.; Measey, M.A.; Danchin, M. Intention to vaccinate against COVID-19 in Australia. *Lancet Infect. Dis.* 2020. [CrossRef]

69. Bell, S.; Clarke, R.; Mounier-Jack, S.; Walker, J.L.; Paterson, P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. *Vaccine* 2020, 38, 7789–7798. [CrossRef]

70. Sherman, S.M.; Smith, I.E.; Sim, J.; Amlot, R.; Cutts, M.; Dasch, H.; Rubin, G.J.; Sevdalis, N. COVID-19 vaccination intention in the UK: Results from the COVID-19 vaccination acceptability study (CoVAccS), a nationally representative cross-sectional survey. *Hum. Vaccines Immunother.* 2020, 1–10. [CrossRef] [PubMed]

71. Zhang, K.C.; Fang, Y.; Cao, H.; Chen, H.; Hu, T.; Chen, Y.Q.; Zhou, X.; Wang, Z. Parental acceptability of COVID-19 vaccination for children under the age of 18 years in China: Cross-sectional online survey. *JMRIR Pediatr. Parent.* 2020. [CrossRef] [PubMed]

72. La Vecchia, C.; Negri, E.; Alicandro, G.; Scarpino, V. Attitudes towards influenza vaccine and a potential COVID-19 vaccine in Italy and differences across occupational groups, September 2020. *Med. Lav.* 2020, 111, 445–448. [CrossRef]

73. Grech, V.; Gauci, C.; Agius, S. Vaccine hesitancy among Maltese healthcare workers toward influenza and novel COVID-19 vaccination. *Early Hum. Dev.* 2020, 105213. [CrossRef]

74. Grech, V.; Gauci, C. Vaccine hesitancy in the University of Malta Faculties of Health Sciences, Dentistry and Medicine vis-a-vis influenza and novel COVID-19 vaccination. *Early Hum. Dev.* 2020, 105258. [CrossRef] [PubMed]

75. Al-Mohaithef, M.; Padhi, B.K. Determinants of COVID-19 Vaccine Acceptance in Saudi Arabia: A Web-Based National Survey. *J. Multidiscip. Healthc.* 2020, 13, 1657–1663. [CrossRef] [PubMed]

76. Phadke, V.K.; Bednarczyk, R.A.; Salmon, D.A.; Omer, S.B. Association between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. *JAMA* 2016, 315, 1149–1158. [CrossRef] [PubMed]

77. Benecke, O.; DeYoung, S.E. Anti-Vaccine Decision-Making and Measles Resurgence in the United States. *Glob. Pediatr. Health* 2019, 6. [CrossRef] [PubMed]

78. Gangarosa, E.J.; Galazka, A.M.; Wolfe, C.R.; Phillips, L.M.; Gangarosa, R.E.; Miller, E.; Chen, R.T. Impact of anti-vaccine movements on pertussis control: The untold story. *Lancet* 1998, 351, 356–361. [CrossRef]

79. Borba, R.C.; Vidal, V.M.; Moreira, L.O. The re-emergency and persistence of vaccine preventable diseases. *An. Acad. Bras. Cienc.* 2015, 87, 1311–1322. [CrossRef]
80. Wong, L.P.; Wong, P.F.; AbuBakar, S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: The way forward for Malaysia, a Southeast Asian country. *Hum. Vaccines Immunother.* 2020, 16, 1511–1520. [CrossRef]

81. Lurie, N.; Saville, M.; Hatchett, R.; Halton, J. Developing Covid-19 vaccines at pandemic speed. *N. Engl. J. Med.* 2020, 382, 1969–1973. [CrossRef]

82. Graham, B.S. Rapid COVID-19 vaccine development. *Science* 2020, 368, 945–946. [CrossRef] [PubMed]

83. Sharma, O.; Sultan, A.A.; Ding, H.; Triggle, C.R. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. *Front. Immunol.* 2020, 11, 585354. [CrossRef] [PubMed]

84. Pogue, K.; Jensen, J.L.; Stancil, C.K.; Ferguson, D.G.; Hughes, S.J.; Mello, E.J.; Burgess, R.; Berges, B.K.; Quaye, A.; Poole, B.D. Influences on Attitudes Regarding Potential COVID-19 Vaccination in the United States. *Vaccines* 2020, 8, 582. [CrossRef] [PubMed]

85. Hamadani, J.D.; Hasan, M.I.; Baldi, A.J.; Hossain, S.J.; Shiraji, S.; Bhuiyan, M.S.A.; Mehrin, S.F.; Fisher, J.; Tofail, F.; Tipu, S.M.U. Immediate impact of stay-at-home orders to control COVID-19 transmission on socioeconomic conditions, food insecurity, mental health, and intimate partner violence in Bangladeshi women and their families: An interrupted time series. *Lancet Glob. Health* 2020, 8, e1380–e1389. [CrossRef]

86. Ridenhour, B.; Kowalik, J.M.; Shay, D.K. Unraveling r 0: Considerations for public health applications. *Am. J. Public Health* 2018, 108, S445–S454. [CrossRef]

87. Billah, M.A.; Miah, M.M.; Khan, M.N. Reproductive number of coronavirus: A systematic review and meta-analysis based on global level evidence. *PLOS ONE* 2020, 15, e0242128. [CrossRef] [PubMed]

88. Anderson, R.M.; Vegvari, C.; Truscott, J.; Collyer, B.S. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination. *Lancet* 2020, 396, 1614–1616. [CrossRef]

89. Britton, T.; Ball, F.; Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. *Science* 2020, 369, 846–849. [CrossRef]

90. Wang, J.; Peng, Y.; Xu, H.; Cui, Z.; Williams, R.O., 3rd. The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation. *AAPS Pharm. Sci. Tech.* 2020, 21, 225. [CrossRef]

91. Teerawattananon, Y.; Dabak, S.V. Reimagining COVID-19 Vaccination Logistics: Five Steps to Take Now. *Nature Publishing Group: London, UK, 2020.*

92. Palamenghi, L.; Barello, S.; Boccia, S.; Graffigna, G. Mistrust in biomedical research and vaccine hesitancy: The forefront challenge in the battle against COVID-19 in Italy. *Eur. J. Epidemiol.* 2020, 35, 785–788. [CrossRef]

93. Weintraub, R.L.; Subramanian, L.; Karlage, A.; Ahmad, I.; Rosenberg, J. COVID-19 Vaccine To Vaccination: Why Leaders Must Invest In Delivery Strategies Now: Analysis describe lessons learned from past pandemics and vaccine campaigns about the path to successful vaccine delivery for COVID-19. *Health Aff.* 2021, 40, 33–41. [CrossRef]

94. Habersaat, K.B.; Betsch, C.; Danchin, M.; Sunstein, C.R.; Böhm, R.; Falk, A.; Brewer, N.T.; Omer, S.B.; Scherzer, M.; Sah, S. Ten considerations for effectively managing the COVID-19 transition. *Nat. Hum. Behav.* 2020, 4, 677–687. [CrossRef] [PubMed]

95. Dodd, R.H.; Cvejic, E.; Bonner, C.; Pickles, K.; McCaffery, K.J.; Sydney Health Literacy Lab COVID-19 Group. Willingness to vaccinate against COVID-19 in Australia. *Lancet Infect. Dis.* 2020. [CrossRef]

96. Nguyen, L.H.; Drew, D.A.; Graham, M.S.; Joshi, A.D.; Guo, C.-G.; Ma, W.; Mehta, R.S.; Warner, E.T.; Sikavi, D.R.; Lo, C.-H. Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. *Lancet Public Health* 2020, 5, e475–e483. [CrossRef]

97. Shaukat, N.; Ali, D.M.; Razzak, J. Physical and mental health impacts of COVID-19 on healthcare workers: A scoping review. *Int. J. Emerg. Med.* 2020, 13, 40. [CrossRef]

98. Nie, Q.; Li, X.; Chen, W.; Liu, D.; Chen, Y.; Li, H.; Li, D.; Tian, M.; Tan, W.; Zai, J. Phylogenetic and phylodynamic analyses of SARS-CoV-2. *Virus Res.* 2020, 287, 198098. [CrossRef]

99. Sallam, M.; Dababseh, D.; Yaseen, A.; Al-Haidar, A.; Ababneh, N.A.; Bakri, F.G.; Mahfazah, A. COVID-19 misinformation: Mere harmless delusions or much more? A knowledge and attitude cross-sectional study among the general public residing in Jordan. *PLoS ONE* 2020, 15, e0243264. [CrossRef]

100. Nyhan, B.; Zeitzoff, T. Conspiracy and misperception belief in the Middle East and North Africa. *J. Politics* 2018, 80, 1400–1404. [CrossRef]

101. Sallam, M.; Dababseh, D.; Yaseen, A.; Al-Haidar, A.; Ababneh, N.A.; Bakri, F.G.; Mahfazah, A. Conspiracy Beliefs Are Associated with Lower Knowledge and Higher Anxiety Levels Regarding COVID-19 among Students at the University of Jordan. *Int. J. Environ. Res. Public Health* 2020, 17, 4915. [CrossRef] [PubMed]

102. Reuben, R.C.; Danladi, M.M.A.; Saleh, D.A.; Ejembi, P.E. Knowledge, Attitudes and Practices Towards COVID-19: An Epidemiological Survey in North-Central Nigeria. *J. Community Health* 2020. [CrossRef] [PubMed]

103. Head, K.J.; Kasting, M.L.; Sturm, L.A.; Hartsocx, J.A.; Zimet, G.D. A National Survey Assessing SARS-CoV-2 Vaccination Intentions: Implications for Future Public Health Communication Efforts. *Sci. Commun.* 2020, 42, 698–723. [CrossRef]